Welcome to our dedicated page for Apollomics news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on Apollomics stock.
Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oncology therapies aimed at targeting specific molecular pathways to combat cancer. With a commitment to harnessing the immune system through combination therapies, Apollomics is at the forefront of developing treatments for difficult-to-treat and treatment-resistant cancers.
Originally known as CBT Pharmaceuticals, Apollomics operates with a clear vision of a world without cancer. The company's lead programs include vebreltinib (APL-101), a selective c-Met inhibitor intended for the treatment of non-small cell lung cancer (NSCLC) and other advanced tumors with c-Met alterations, and uproleselan (APL-106), an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy for acute myeloid leukemia (AML).
Apollomics' commitment to rigorous scientific research is evident in their broad pipeline, consisting of nine drug candidates across multiple programs, six of which are currently in clinical stages of development. The company has built strong partnerships and in-licensed assets to advance both preclinical and clinical development programs. These partnerships play a crucial role in enhancing Apollomics' pipeline and expanding the patient populations served.
Recent milestones include:
- Presentation of interim data from the Phase 2 KUNPENG and SPARTA trials, highlighting the efficacy of vebreltinib in NSCLC patients with MetExon14 skipping mutations.
- Completion of patient enrollment in the Phase 3 bridging study of uproleselan in China, targeting relapsed or refractory AML.
- Conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib, making it the first c-Met inhibitor approved for CNS tumors with c-Met alterations.
As the company continues to advance its clinical trials and expand its therapeutic potential globally, Apollomics remains focused on providing transformative treatments that significantly improve patient outcomes.
Apollomics Inc. (Nasdaq: APLM) presented data on vebreltinib for non-small cell lung cancer (NSCLC) with METex14 skipping mutations at the ESMO Congress 2024. Key findings include:
1. Efficacy in both treatment-naïve and previously treated patients:
- Treatment-naïve: 66.7% overall response rate (ORR), 17.3 months median duration of response (DOR), 13.8 months median progression-free survival (PFS)
- Previously treated: 61.1% ORR, 16.7 months median DOR, 7.4 months median PFS
2. Efficacy regardless of MET gene copy number (GCN):
- GCN<4: 67.8% ORR
- GCN<6: 69.2% ORR
- GCN>4: 100% ORR (5/5 patients)
3. Safety profile: 48.1% of patients experienced grade 3 or higher treatment-related adverse events, with edema being most common (16.7%). No deaths were reported due to treatment-emergent adverse events.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York, NY.
Key details of Apollomics' participation include:
- An on-demand company presentation available from September 9, 2024, at 7:00 am ET
- Presenters: Guo-Liang Yu, PhD (Chairman and CEO) and Matthew Plunkett, PhD (CFO)
- Management will be available for virtual one-on-one meetings
- The presentation will be accessible on the company's website
Apollomics focuses on developing oncology drug candidates for difficult-to-treat and treatment-resistant cancers.
Apollomics Inc. (Nasdaq: APLM) reported its first half 2024 financial results and clinical progress for vebreltinib. Key highlights include:
1. Promising preliminary results from the vebreltinib program for tumors with Met dysregulation, including non-CNS MET fusion tumors and NSCLC with MET amplification.
2. Cash position of $25.9 million as of June 30, 2024, with runway into Q3 2025.
3. R&D expenses of $16.9 million and G&A expenses of $10.2 million for H1 2024.
4. Net loss of $(35.2) million, or $(0.38) per share, including a $10 million impairment loss for uproleselan.
5. Strategic focus on vebreltinib for NSCLC patients with Met Amplification.
6. Raised $5.8 million in a PIPE financing in May 2024.
Apollomics Inc. (Nasdaq: APLM) announced positive preliminary data from its Phase 2 SPARTA trial of vebreltinib in patients with non-CNS MET fusion solid tumors. The study showed a 43% overall response rate, with six confirmed responses out of 14 patients. Key highlights include:
- One complete response in metastatic non-small cell lung cancer (NSCLC)
- Five partial responses across NSCLC, pancreatic cancer, and intrahepatic bile duct cancer
- Median overall survival of 12.4 months
- Median progression-free survival of 4.5 months
- Median duration of response of 5.6 months
- Longest ongoing response of 18 months
The company believes these results support vebreltinib's potential as a targeted therapy for tumors with MET alterations, which occur in 0.1-0.3% of solid tumors.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company focusing on oncology drug candidates for difficult-to-treat and treatment-resistant cancers, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The event is scheduled for August 13-15, 2024, in Boston, MA.
Key details of Apollomics' presentation:
- Date and Time: Tuesday, August 14, 2024, at 9:30 am ET
- Location: InterContinental Boston Hotel
- Presenter: Matthew Plunkett, PhD, Chief Financial Officer
The company management will be available for one-on-one meetings during the conference. Interested investors can contact their Canaccord Genuity representative to schedule meetings. A webcast link for the presentation will be available on the company's website under the Investors section on the Events page.
Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company, has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. The company now has until January 13, 2025 to meet the $1.00 per share minimum bid price for its Ordinary Shares. This extension follows a previous notice of non-compliance received on January 16, 2024.
To regain compliance, Apollomics must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the deadline. If unsuccessful, the company may face delisting, with an option to appeal to a Nasdaq Hearings Panel. Apollomics is actively monitoring its stock price and exploring options to meet the requirement, though success is not guaranteed.
Apollomics (Nasdaq: APLM) announced a revised strategic focus on the clinical development of vebreltinib for NSCLC patients with Met Amplification mutations and significant changes in its executive leadership. The SPARTA Phase 2 trial will concentrate on this high-need patient population. Co-founder and President Sanjeev Redkar, Ph.D., and Chief Medical Officer Peony Yu, M.D., will transition to consulting roles in August. These changes are part of a broader cost-reduction strategy expected to cut operating expenses by over 50% and extend funding until Q3 2025.
Apollomics aims to generate additional clinical data to support regulatory submissions, with updates anticipated in 2024 and 2025. The departures of key executives are aligned with the company's resource needs and focus on maximizing the efficient use of capital.
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
FAQ
What is the current stock price of Apollomics (APLM)?
What is the market cap of Apollomics (APLM)?
What does Apollomics Inc. do?
What are Apollomics' lead programs?
What recent achievements has Apollomics made?
How many drug candidates does Apollomics have in its pipeline?
What is the significance of Apollomics' partnerships?
How does vebreltinib work?
What is uproleselan used for?
What are the key focuses of Apollomics' current research?
What is the significance of Apollomics' recent conditional approval in China?
How does Apollomics plan to continue its growth and advancements in oncology treatments?
